Primary endpoint met in phase 3 trial with finerenone in patients with HFmrEF/HFpEF
In the phase 3 FINEARTS-HF trial, finerenone reduced the composite primary outcome of CV death and total HF events compared with placebo when added to usual therapy in patients with HFmrEF/HFpEF.
The phase 3 FINEARTS-HF trial with the selective, nonsteroidal MRA finerenone in patients with HFmrEF/HFpEF met its primary composite endpoint. Compared with placebo, finerenone reduced the composite primary endpoint of CV death and total (first and recurrent) HF events, defined as HF hospitalizations or urgent HF visits, when added to usual therapy in patients with HFmrEF/HFpEF. The safety and tolerability profile of finerenone in FINEARTS-HF was consistent with previous findings.
The FINEARTS-HF trial is randomized, double-blind, placebo-controlled, multicenter, event-driven phase 3 trial to evaluate the efficacy and safety of finerenone versus placebo in patients with symptomatic HF (NYHA class II-IV) with LVEF of ≥40%. This trial included ~6000 patients who were randomized to either finerenone or placebo once daily for up to 42 months.
The results of FINEARTS-HF will be presented at ESC Congress 2024.